Company / Cost of Revenue
ATOSSA THERAPEUTICS, INC. Cost of Revenue History
FY2012-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$132.4K
FY2016
5-year range
$0 / $345.5K
FY2012-FY2016
Trend
-
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $345,519 to $132,411 over the past 2 years.
Based on SEC 10-K filings.
$132,411 in FY2016 with a 3-year CAGR of +54.7%.
Improved from $345,519 to $132,411 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +54.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +54.7%, indicating consistent growth.
- Peak cost of revenue was recorded in FY2014.
- Lowest cost of revenue in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -15.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $132.4K | - |
| FY2015 | $0 | -100.0% |
| FY2014 | $345.5K | +866.6% |
| FY2013 | $35.7K | +592.2% |
| FY2012 | $5.2K | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026